皮膚科治療薬の世界市場レポート 2025年

皮膚科治療薬市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR9.6％で317億5,000万米ドルに成長します。予測期間の成長は、生物製剤と標的治療の進歩、遠隔皮膚科学とデジタルヘルスの導入拡大、生活習慣に関連する皮膚疾患の有病率の上昇、個別化医療と再生医療に対する需要の高まり、微生物ベースの皮膚科治療における研究の拡大に起因すると考えられます。この期間に予想される主な動向には、ナノテクノロジーを利用したドラッグデリバリー、AIを活用した皮膚科診断、微生物を標的とした治療、皮膚再生のための3Dバイオプリンティング、遺伝子編集、RNAを利用した治療などがあります。

美容皮膚科処置の需要増加が皮膚科治療薬市場の拡大を牽引すると予想されます。美容皮膚科は、様々な非外科的治療や処置を通じて人の外見を向上させる専門分野です。このような需要の高まりは、美容治療に対する消費者の意識の高まり、スキンケア技術の進歩、見た目を改善し老化を防ぐための非侵襲的な施術への嗜好などが背景にあります。アンチエイジングや肌の若返りなどの美容皮膚科治療の人気が高まっていることから、安全で効果的、かつ低侵襲なソリューションを提供する先進的な皮膚科治療薬の開発が進んでいます。例えば、2023年1月、国際美容形成外科学会は、1,280万件以上の外科的手術と1,750万件以上の非外科的手術が世界的に行われ、前期から19.3％増加したと報告しました。さらに2022年には、世界中の形成外科医が1,490万件以上の外科手術と1,880万件以上の非外科手術を実施し、総治療件数が11.2％増加しました。その結果、美容皮膚科手術の増加が皮膚科治療薬市場の拡大に拍車をかけています。

皮膚科治療薬市場の主要企業は、乾癬、アトピー性皮膚炎、膿疱性汗腺炎などの慢性皮膚疾患に対処するための生物学的治療法の開発に注力しています。生物学的製剤は特定の免疫経路を標的とし、従来の治療と比較してより効果的で長期にわたる緩和を提供します。2024年9月、米国の製薬会社イーライリリー・アンド・カンパニーは、12歳以上の中等度から重度のアトピー性皮膚炎患者を対象としたインターロイキン13（IL-13）阻害薬であるエブグリス（一般名：レブリキズマブ）の承認を取得しました。今回の承認は、外用療法で十分な症状コントロールが得られない患者さんに生物学的製剤による新たな治療選択肢を提供するものであり、大きな進歩です。エブグリスは、中等症から重症のアトピー性皮膚炎に伴う強いかゆみと皮膚の炎症を抑えることで、患者のQOLの向上を目指します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界皮膚科治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の皮膚科治療薬市場：成長率分析
• 世界の皮膚科治療薬市場の実績：規模と成長, 2019-2024
• 世界の皮膚科治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界皮膚科治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の皮膚科治療薬市場：薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• コルチコステロイド
• レチノイド
• 抗生物質
• 抗真菌薬
• カルシニューリン阻害剤
• その他の薬物クラス
• 世界の皮膚科治療薬市場管理局による、実績と予測, 2019-2024, 2024-2029F, 2034F
• 局所投与
• 経口投与
• 非経口投与
• 世界の皮膚科治療薬市場：適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ニキビ
• 乾癬
• 酒さ様皮膚炎
• 脱毛症
• その他の適応症
• 世界の皮膚科治療薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• その他の流通チャネル
• 世界の皮膚科治療薬市場コルチコステロイドの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 局所コルチコステロイド
• 経口コルチコステロイド
• 注射用コルチコステロイド
• 世界の皮膚科治療薬市場レチノイドの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 局所レチノイド
• 経口レチノイド
• 世界の皮膚科治療薬市場抗生物質の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 局所抗生物質
• 経口抗生物質
• 世界の皮膚科治療薬市場抗真菌薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 局所抗真菌薬
• 経口抗真菌薬
• 世界の皮膚科治療薬市場カルシニューリン阻害剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 局所カルシニューリン阻害剤
• 全身性カルシニューリン阻害剤
• 世界の皮膚科治療薬市場、その他の薬物クラスのタイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 生物学的製剤
• JAK阻害剤
• 抗ヒスタミン薬
• 光線力学療法剤

第7章 地域別・国別分析

• 世界の皮膚科治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の皮膚科治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 皮膚科治療薬市場：競合情勢
• 皮膚科治療薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Novartis AG
• GlaxoSmithKline Plc
• Eli Lilly and Company
• Amgen Inc.
• Bausch Health Companies Inc.
• Organon International
• Galderma
• Incyte Corporation
• Glenmark Pharmaceuticals Ltd.
• Mayne Pharma Group Limited
• Dermavant Sciences Inc.
• Taro Pharmaceutical Industries Ltd.
• Biofrontera AG
• Almirall SA
• UCB SA

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 皮膚科治療薬市場2029：新たな機会を提供する国
• 皮膚科治療薬市場2029：新たな機会を提供するセグメント
• 皮膚科治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Dermatological drugs are medications formulated to treat conditions affecting the skin, hair, and nails by reducing inflammation, controlling infections, and managing symptoms such as itching and redness. These drugs are essential in dermatology, helping to address both common and severe skin disorders while enhancing patient comfort and quality of life.

The primary drug classes in dermatological treatments include corticosteroids, retinoids, antibiotics, antifungals, calcineurin inhibitors, and others. Corticosteroids are a class of steroid hormones that reduce inflammation and suppress immune system activity by mimicking cortisol, a natural hormone produced by the adrenal glands. These drugs can be administered through various routes, including topical, oral, and parenteral administration. They are used to treat multiple conditions such as acne, psoriasis, rosacea, alopecia, and more. Distribution channels include hospital pharmacies, retail pharmacies, and other outlets.

The dermatological drugs market research report is one of a series of new reports from The Business Research Company that provides dermatological drugs market statistics, including dermatological drugs industry global market size, regional shares, competitors with a dermatological drugs market share, detailed dermatological drugs market segments, market trends and opportunities, and any further data you may need to thrive in the dermatological drugs industry. This dermatological drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The dermatological drugs market size has grown strongly in recent years. It will grow from $20.06 billion in 2024 to $22.04 billion in 2025 at a compound annual growth rate (CAGR) of 9.8%. The growth during the historic period was driven by the rising prevalence of skin disorders, advancements in drug formulation and delivery, increasing awareness of skincare and aesthetics, the expansion of the aging population, and the growing demand for over-the-counter dermatological products.

The dermatological drugs market size is expected to see strong growth in the next few years. It will grow to $31.75 billion in 2029 at a compound annual growth rate (CAGR) of 9.6%. The projected growth in the forecast period can be attributed to advancements in biologics and targeted therapies, the increasing adoption of teledermatology and digital health, a rising prevalence of lifestyle-related skin conditions, growing demand for personalized and regenerative medicine, and expanding research in microbiome-based dermatological treatments. Key trends expected in this period include nanotechnology-based drug delivery, AI-driven dermatological diagnostics, microbiome-targeted therapies, 3D bioprinting for skin regeneration, gene editing, and RNA-based treatments.

The increasing demand for cosmetic dermatology procedures is expected to drive the expansion of the dermatological drugs market. Cosmetic dermatology is a specialized field that enhances a person's appearance through various non-surgical treatments and procedures. This growing demand is fueled by heightened consumer awareness of aesthetic treatments, advancements in skincare technology, and a preference for non-invasive procedures to improve appearance and counteract aging. The rising popularity of cosmetic dermatology treatments, such as anti-aging and skin rejuvenation procedures, is leading to the development of advanced dermatological drugs that provide safe, effective, and minimally invasive solutions. For example, in January 2023, the International Society of Aesthetic Plastic Surgery reported that over 12.8 million surgical and 17.5 million non-surgical procedures were performed globally, reflecting a 19.3% increase from the previous period. Additionally, in 2022, plastic surgeons worldwide conducted more than 14.9 million surgical and 18.8 million non-surgical procedures, marking an 11.2% rise in total treatments. As a result, the growing number of cosmetic dermatology procedures is fueling the expansion of the dermatological drugs market.

Leading companies in the dermatological drugs market are focusing on developing biologic treatments to address chronic skin conditions such as psoriasis, atopic dermatitis, and hidradenitis suppurativa. Biologic therapies target specific immune pathways, offering more effective and long-lasting relief compared to traditional treatments. In September 2024, Eli Lilly and Company, a US-based pharmaceutical firm, received approval for Ebglyss (lebrikizumab), an interleukin-13 (IL-13) inhibitor designed to treat moderate-to-severe atopic dermatitis in patients aged 12 and older. This approval represents a significant advancement, providing a new biologic treatment option for individuals who have not achieved sufficient symptom control with topical therapies. Ebglyss aims to enhance patients' quality of life by reducing severe itching and skin inflammation associated with moderate-to-severe atopic dermatitis.

In September 2024, Organon, a US-based pharmaceutical company, acquired Dermavant Sciences Ltd. for $1.2 billion. This acquisition brings Dermavant's flagship product, VTAMA (tapinarof) cream, 1%, into Organon's portfolio. VTAMA is a non-steroidal topical treatment approved by the US Food and Drug Administration (FDA) for mild, moderate, and severe plaque psoriasis in adults. Dermavant Sciences Ltd. is a US-based immunodermatology company specializing in the development and commercialization of innovative dermatological treatments.

Major players in the dermatological drugs market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Bayer AG, AstraZeneca plc, Novartis AG, GlaxoSmithKline Plc, Eli Lilly and Company, Amgen Inc., Bausch Health Companies Inc., Organon International, Galderma, Incyte Corporation, Glenmark Pharmaceuticals Ltd., Mayne Pharma Group Limited, Dermavant Sciences Inc., Taro Pharmaceutical Industries Ltd., Biofrontera AG, Almirall SA, UCB SA, LEO Pharma A/S, and Dermira Inc.

North America was the largest region in the dermatological drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in dermatological drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the dermatological drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The dermatological drugs market consists of sales of creams, ointments, gels, and lotions. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Dermatological Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on dermatological drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for dermatological drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The dermatological drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Corticosteroids; Retinoids; Antibiotics; Antifungals; Calcineurin Inhibitors; Other Drug Classes
• 2) By Administration: Topical Administration; Oral Administration; Parenteral Administration
• 3) By Indication: Acne; Psoriasis; Rosacea; Alopecia; Other Indications
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Other Distribution Channels
• Subsegments:
• 1) By Corticosteroids: Topical Corticosteroids; Oral Corticosteroids; Injectable Corticosteroids
• 2) By Retinoids: Topical Retinoids; Oral Retinoids
• 3) By Antibiotics: Topical Antibiotics; Oral Antibiotics
• 4) By Antifungals: Topical Antifungals; Oral Antifungals
• 5) By Calcineurin Inhibitors: Topical Calcineurin Inhibitors; Systemic Calcineurin Inhibitors
• 6) By Other Drug Classes: Biologics; JAK Inhibitors; Antihistamines; Photodynamic Therapy Agents
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; AbbVie Inc.; Bayer AG; AstraZeneca plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Dermatological Drugs Market Characteristics

3. Dermatological Drugs Market Trends And Strategies

4. Dermatological Drugs Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Dermatological Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Dermatological Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Dermatological Drugs Market Growth Rate Analysis
• 5.4. Global Dermatological Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Dermatological Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Dermatological Drugs Total Addressable Market (TAM)

6. Dermatological Drugs Market Segmentation

• 6.1. Global Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Corticosteroids
• Retinoids
• Antibiotics
• Antifungals
• Calcineurin Inhibitors
• Other Drug Classes
• 6.2. Global Dermatological Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Topical Administration
• Oral Administration
• Parenteral Administration
• 6.3. Global Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acne
• Psoriasis
• Rosacea
• Alopecia
• Other Indications
• 6.4. Global Dermatological Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Other Distribution Channels
• 6.5. Global Dermatological Drugs Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Topical Corticosteroids
• Oral Corticosteroids
• Injectable Corticosteroids
• 6.6. Global Dermatological Drugs Market, Sub-Segmentation Of Retinoids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Topical Retinoids
• Oral Retinoids
• 6.7. Global Dermatological Drugs Market, Sub-Segmentation Of Antibiotics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Topical Antibiotics
• Oral Antibiotics
• 6.8. Global Dermatological Drugs Market, Sub-Segmentation Of Antifungals, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Topical Antifungals
• Oral Antifungals
• 6.9. Global Dermatological Drugs Market, Sub-Segmentation Of Calcineurin Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Topical Calcineurin Inhibitors
• Systemic Calcineurin Inhibitors
• 6.10. Global Dermatological Drugs Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Biologics
• JAK Inhibitors
• Antihistamines
• Photodynamic Therapy Agents

7. Dermatological Drugs Market Regional And Country Analysis

• 7.1. Global Dermatological Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Dermatological Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Dermatological Drugs Market

• 8.1. Asia-Pacific Dermatological Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Dermatological Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Dermatological Drugs Market

• 9.1. China Dermatological Drugs Market Overview
• 9.2. China Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Dermatological Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Dermatological Drugs Market

• 10.1. India Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Dermatological Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Dermatological Drugs Market

• 11.1. Japan Dermatological Drugs Market Overview
• 11.2. Japan Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Dermatological Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Dermatological Drugs Market

• 12.1. Australia Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Dermatological Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Dermatological Drugs Market

• 13.1. Indonesia Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Dermatological Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Dermatological Drugs Market

• 14.1. South Korea Dermatological Drugs Market Overview
• 14.2. South Korea Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Dermatological Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Dermatological Drugs Market

• 15.1. Western Europe Dermatological Drugs Market Overview
• 15.2. Western Europe Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Dermatological Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Dermatological Drugs Market

• 16.1. UK Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Dermatological Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Dermatological Drugs Market

• 17.1. Germany Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Dermatological Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Dermatological Drugs Market

• 18.1. France Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Dermatological Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Dermatological Drugs Market

• 19.1. Italy Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Dermatological Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Dermatological Drugs Market

• 20.1. Spain Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Dermatological Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Dermatological Drugs Market

• 21.1. Eastern Europe Dermatological Drugs Market Overview
• 21.2. Eastern Europe Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Dermatological Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Dermatological Drugs Market

• 22.1. Russia Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Dermatological Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Dermatological Drugs Market

• 23.1. North America Dermatological Drugs Market Overview
• 23.2. North America Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Dermatological Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Dermatological Drugs Market

• 24.1. USA Dermatological Drugs Market Overview
• 24.2. USA Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Dermatological Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Dermatological Drugs Market

• 25.1. Canada Dermatological Drugs Market Overview
• 25.2. Canada Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Dermatological Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Dermatological Drugs Market

• 26.1. South America Dermatological Drugs Market Overview
• 26.2. South America Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Dermatological Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Dermatological Drugs Market

• 27.1. Brazil Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Dermatological Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Dermatological Drugs Market

• 28.1. Middle East Dermatological Drugs Market Overview
• 28.2. Middle East Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Dermatological Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Dermatological Drugs Market

• 29.1. Africa Dermatological Drugs Market Overview
• 29.2. Africa Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Dermatological Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Dermatological Drugs Market Competitive Landscape And Company Profiles

• 30.1. Dermatological Drugs Market Competitive Landscape
• 30.2. Dermatological Drugs Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

31. Dermatological Drugs Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. GlaxoSmithKline Plc
• 31.3. Eli Lilly and Company
• 31.4. Amgen Inc.
• 31.5. Bausch Health Companies Inc.
• 31.6. Organon International
• 31.7. Galderma
• 31.8. Incyte Corporation
• 31.9. Glenmark Pharmaceuticals Ltd.
• 31.10. Mayne Pharma Group Limited
• 31.11. Dermavant Sciences Inc.
• 31.12. Taro Pharmaceutical Industries Ltd.
• 31.13. Biofrontera AG
• 31.14. Almirall SA
• 31.15. UCB SA

32. Global Dermatological Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Dermatological Drugs Market

34. Recent Developments In The Dermatological Drugs Market

35. Dermatological Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Dermatological Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Dermatological Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Dermatological Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer